Radium-223 Plus Sipuleucel-T Yields Mixed Results in mCRPC

Published: Friday, Feb 14, 2020
Catherine H. Marshall, MD, MPH, assistant professor of oncology of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Catherine H. Marshall, MD, MPH

Combination therapy with radium-223 (Xofigo) and sipuleucel-T (Provenge) yielded conflicting results in patients with metastatic castration-resistant prostate cancer (mCRPC), according to data shared at the 2020 Genitourinary Cancers Symposium. The regimen enhanced clinical outcomes across several key benchmarks compared with sipuleucel-T alone; however, immune responses were superior with single-agent sipuleucel-T versus the doublet.

Adverse event rates were similar between the 2 groups, including constitutional, hematologic, gastrointestinal, cardiac, and others.


  1. Marshall CH, Park JC, Fu W, et al. Randomized phase 2 study of sipuleucel-T (Sip-T) with or without radium-223 (Ra-223) in men with bone-metastatic castration resistant prostate cancer. Presented at: 2020 Genitourinary Cancers Symposium; February 13-15, 2020; San Francisco, CA. Abstract 130.
  2. Shore ND, Mantz CA, Dosoretz DE, et al. Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer. Cancer Control. 2013;20(1):7-16.
<<< View more from the 2020 Genitourinary Cancers Symposium
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication